A 55-year-old man with acute angle-closure glaucoma presents with severe eye pain, blurred vision, and a hazy cornea. Topical and systemic agents have been initiated. Which adrenergic agonist is the drug of choice for long-term management to reduce intraocular pressure by decreasing aqueous humor production?

Explanation

## Clinical Context In acute angle-closure glaucoma, after emergency management (pilocarpine, acetazolamide, IV mannitol, and sometimes laser peripheral iridotomy), long-term IOP reduction requires agents that decrease aqueous humor production. **Brimonidine** (an α2-adrenergic agonist) is the preferred adrenergic agent for chronic glaucoma management. ## Why Brimonidine is Preferred **Key Point:** Brimonidine is a selective α2-adrenergic agonist that decreases aqueous humor production and increases uveoscleral outflow, making it ideal for long-term glaucoma management. | Agent | Receptor | Mechanism in Glaucoma | Aqueous Production | Outflow | Systemic Effects | **Chronic Use** | |-------|----------|----------------------|-------------------|---------|------------------|----------------| | **Brimonidine** | **α2** | **↓ Production + ↑ Outflow** | **↓↓** | **↑** | **Minimal** | **✓ Preferred** | | Epinephrine | α1, β1 | ↑ Outflow (minor) | ↓ (minimal) | ↑ | Tachycardia, tremor | ✗ Avoid | | Phenylephrine | α1 | Mydriasis (risk of angle-closure) | ↓ (minimal) | ↑ (minor) | HTN, reflex bradycardia | ✗ Contraindicated | | Dobutamine | β1 | Inotropy (no IOP effect) | — | — | Tachycardia, HTN | ✗ Not for glaucoma | ## Mechanism of Brimonidine in Glaucoma 1. **α2-adrenergic receptor activation** (presynaptic and postsynaptic) 2. **↓ Aqueous humor production** → Reduced ciliary body secretion (primary effect) 3. **↑ Uveoscleral outflow** → Enhanced drainage via unconventional pathway 4. **Net result:** IOP reduction of 15–25% without systemic side effects **High-Yield:** Brimonidine is the **only adrenergic agonist** recommended for chronic glaucoma. Other α-agonists (phenylephrine, epinephrine) are avoided because they may precipitate angle-closure or cause systemic toxicity. ## Why Other Options Fail **Epinephrine:** Historically used, but causes mydriasis (pupil dilation) and may precipitate angle-closure in susceptible patients. Also causes tremor, tachycardia, and is now replaced by brimonidine. **Phenylephrine:** Pure α1-agonist. Causes mydriasis and can precipitate acute angle-closure glaucoma — **contraindicated** in angle-closure disease. **Dobutamine:** β1-agonist with no effect on IOP. Used for cardiac support, not glaucoma. ## Dosing & Administration - **Brimonidine ophthalmic solution:** 0.15–0.2% drops, 2–3 times daily - Onset: 30 minutes; peak effect: 2 hours - Duration: 12 hours **Clinical Pearl:** Brimonidine may cause conjunctival blanching and mild sedation (due to CNS α2-receptor activation), but systemic absorption is minimal with topical dosing. Tolerance can develop after 1–3 months in some patients ("tachyphylaxis"). ## Guideline Reference [cite:American Academy of Ophthalmology, Glaucoma Guidelines] recommends brimonidine as a first-line topical agent for IOP reduction in chronic glaucoma.